Newly Discovered RNA Molecule Offers Potential Breakthrough in Cholesterol Control and Heart Disease Prevention
A groundbreaking study has identified a previously overlooked small RNA molecule, tsRNA-Glu-CTC, that plays a critical role in regulating cholesterol production and the development of heart disease, offering a potential new avenue for therapeutic intervention.
Researchers have long sought to understand the complex mechanisms governing cholesterol metabolism, a key factor in cardiovascular health. This new discovery, published in Nature Communications, sheds light on a previously unknown regulator and could pave the way for more effective treatments for high cholesterol and atherosclerosis.
Unveiling tsRNA-Glu-CTC: A Key Regulator of Cholesterol
Using a novel sequencing technology called PANDORA-seq – developed at UC Riverside – scientists were able to detect hidden types of small RNAs within the liver, the central organ for cholesterol metabolism. Their research revealed that tsRNA-Glu-CTC is remarkably abundant in the liver, accounting for over 65% of all detectable tRNA-derived small RNAs. Importantly, the molecule’s levels respond directly to fluctuations in cholesterol levels. The initial study was conducted using mouse models.
The research team established a direct link between tsRNA-Glu-CTC and SREBP2 (Sterol Regulatory Element-Binding Protein 2), often referred to as the “master regulator” of cholesterol production. “We found that when tsRNA-Glu-CTC levels rise, it boosts SREBP2 activity, which switches on the genes that synthesize cholesterol,” explained a lead researcher. “This mechanism directly contributes to higher cholesterol levels and increases the risk of atherosclerosis, or the clogging of arteries.”
The Threat of Atherosclerosis
Atherosclerosis, a widespread and serious condition, develops through the gradual buildup of plaque – comprised of cholesterol, fat, and other substances – within the arteries. This narrowing restricts blood flow, depriving tissues and organs of vital oxygen. According to the National Institutes of Health, approximately 50% of Americans aged 45 to 84 are living with undiagnosed atherosclerosis, highlighting the significant public health impact of this disease.
Targeting tsRNA-Glu-CTC: A Novel Therapeutic Approach
In their mouse models, researchers successfully employed an antisense oligonucleotide (ASO) – a genetic material designed to block RNA – to reduce tsRNA-Glu-CTC levels. This intervention resulted in a measurable decrease in cholesterol and a lessening of the severity of atherosclerosis.
This approach offers a distinct advantage over existing cholesterol medications, such as statins, which operate further along the metabolic pathway. “By targeting the molecule that initiates the cholesterol production boost, it may be possible to achieve a more fundamental and earlier regulation of the process,” a senior official stated.
Furthermore, the team discovered that the naturally occurring, chemically modified form of tsRNA-Glu-CTC was more effective at regulating cholesterol than its synthetic counterparts, a finding that could be instrumental in the development of future, targeted drugs.
Human Relevance and Future Directions
While the initial research was performed in mice, the findings demonstrate strong relevance to human physiology. Analysis of human blood samples revealed a correlation between elevated levels of tsRNA-Glu-CTC and higher circulating cholesterol, suggesting the newly discovered regulatory mechanism is active in humans.
“Our study marks the first evidence that a tsRNA can directly influence cholesterol metabolism and heart disease, pointing to a new direction for preventing cardiovascular events,” the lead researcher concluded.
The research involved contributions from scientists at UCR, the University of Utah School of Medicine, New York Institute of Technology, University of Nevada, Reno School of Medicine, and State University of New York, Albany. The study was supported by grants from the National Institutes of Health.
